Product logins

Find logins to all Clarivate products below.


Osteoarthritic Pain | Treatment Algorithms | Claims Data Analysis | US | 2019

Osteoarthritic (OA) pain is the second-largest segment of the chronic pain therapy market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. Yet a comprehensively effective and tolerable analgesic class alternative has not become available for this indication in nearly two decades. A successful launch of a new analgesic requires a deep understanding of current treatment patterns in this highly generic market. Over the past few years, several new therapies have launched for OA pain, providing incremental safety, tolerability, and/or dosing benefits to overcome drawbacks of the current standards of care─nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics─but how have agents in these drug classes, particularly brand-only products, fared in this highly generic market in which cost-effectiveness is a primary driver of coverage?

Questions answered:

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OA pain patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OA pain patients?
  • How have branded agents such as abuse-deterrent opioid analgesics been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of OA pain patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of OA pain patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description:

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…